Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma

Cell Cycle

Volumn 13, Issue 10, 2014, Pages 1560-1570

  Friesen, Claudia ^a   Hormann, Inis ^a   Roscher, Mareike ^a   Fichtner, Iduna ^b   Alt, Andreas ^a   Hilger, Ralf ^c   Debatin, Klaus Michael ^d   Miltner, Erich ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; cAMP; Chemoresistance; Chemotherapy; D; Glioblastoma; Glioblastoma stem cells; L methadone; Opioid receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIC AMP; DOXORUBICIN; METHADONE; METHYLXANTHINE; NALOXONE; OPIATE RECEPTOR; PROTEIN BCL XL; X LINKED INHIBITOR OF APOPTOSIS; MU OPIATE RECEPTOR;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIZATION; DRUG TRANSPORT; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; RECEPTOR DOWN REGULATION; AGONISTS; ANIMAL; BRAIN NEOPLASMS; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; DOWN-REGULATION; DOXORUBICIN; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; METHADONE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; RECEPTORS, OPIOID, MU;

EID: 84900523177     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28493     Document Type: Article

References (60)

1. Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 2008; 10:198-206; PMID:18323016
2. Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 2013; 4:502-30; PMID:23594434
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60; PMID:17051156; http://dx.doi.org/10.1038/nature05236
4. Würth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, Parodi A, Sirito R, Massollo M, Marini C, Zona G, et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle 2013; 12:145-56; PMID:23255107; http://dx.doi.org/10.4161/cc.23050
5. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, Tanino M, Nishihara H, Tanaka S. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 2008; 18:1037-46; PMID:18679414; http://dx.doi.org/10. 1038/cr.2008.270
6. Iwanami A, Cloughesy TF, Cavenee WK, Mischel PS. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle 2013; 12:1473-4; PMID:23624839; http://dx.doi.org/10.4161/cc.24747
7. Insel PA, Zhang L, Murray F, Yokouchi H, Zambon AC. Cyclic AMP is both a pro-apoptotic and antiapoptotic second messenger. Acta Physiol (Oxf) 2012; 204:277-87; PMID:21385327; http://dx.doi.org/10.1111/j.1748-1716.2011.02273.x
8. Frisch SM. cAMP takes control. Nat Cell Biol 2000; 2:E167-8; PMID:10980716; http://dx.doi.org/10.1038/35023650
9. Safa M, Kazemi A, Zand H, Azarkeivan A, Zaker F, Hayat P. Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues. Apoptosis 2010; 15:196-203; PMID:19882354; http://dx.doi.org/10.1007/s10495-009-0417-8
10. Naderi EH, Findley HW, Ruud E, Blomhoff HK, Naderi S. Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood 2009; 114:608-18; PMID:19451550; http://dx.doi.org/10.1182/blood-2009-02-204883
11. Standifer KM, Pasternak GW. G proteins and opioid receptor-mediated signalling. Cell Signal 1997; 9:237-48; PMID:9218123; http://dx.doi.org/10.1016/ S0898-6568(96)00174-X
12. Friesen C, Roscher M, Alt A, Miltner E. Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, kills leukemia cells and overcomes chemoresistance. Cancer Res 2008; 68:6059-64; PMID:18676827; http://dx.doi.org/10.1158/0008-5472.CAN-08-1227
13. Friesen C, Roscher M, Hormann I, Fichtner I, Alt A, Hilger RA, Debatin KM, Miltner E. Cell death sensitization of leukemia cells by opioid receptor activation. Oncotarget 2013; 4:677-90; PMID:23633472
14. Singh A, Jayanthan A, Farran A, Elwi AN, Kim SW, Farran P, Narendran A. Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition. Leuk Res 2011; 35:1649-57; PMID:21798596; http://dx.doi.org/10.1016/j.leukres. 2011.06.035
15. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604; PMID:12154352; http://dx.doi.org/10.1038/nrc864
16. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2:574-7; PMID:8616718; http://dx.doi.org/10.1038/nm0596-574
17. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-6; PMID:11048727; http://dx.doi.org/10.1038/35037710
18. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22:8543-67; PMID:14634618; http://dx.doi.org/10.1038/sj.onc.1207107
19. LaCasse EC, Baird S, Korneluk RGK, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17:3247-59; PMID:9916987; http://dx.doi.org/10.1038/sj.onc.1202569
20. Guensberg P, Wacheck V, Lucas T, Monia B, Pehamberger H, Eichler HG, Jansen B. Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy 2002; 48:189-95; PMID:12218266; http://dx.doi.org/10.1159/ 000063873
21. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, Boeckers T, Debatin KM, Fulda S. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009; 11:743-52; PMID:19649204
22. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, Steinbrecher A, Ullrich W, Bogdahn U. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001; 92:1936-42; PMID:11745268; http://dx.doi.org/10.1002/1097- 0142(20011001)92:7〈1936:: AID-CNCR1712〉3.0.CO;2-H
23. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11:1029-33; PMID:11038041; http://dx.doi.org/10.1023/A: 1008365716693
24. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008; 68:6043-8; PMID:18676824; http://dx.doi.org/10.1158/0008-5472. CAN-08-1079
25. Hussaini IM, Carpenter JE, Redpath GT, Sando JJ, Shaffrey ME, Vandenberg SR. Protein kinase C-eta regulates resistance to UV- and gamma-irradiation- induced apoptosis in glioblastoma cells by preventing caspase-9 activation. Neuro Oncol 2002; 4:9-21; PMID:11772428
26. Bouër R, Barthe L, Philibert C, Tournaire C, Woodley J, Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol 1999; 13:494-500; PMID:10456292; http://dx.doi.org/10. 1111/j.1472-8206.1999.tb00009.x
27. Callaghan R, Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem 1993; 268:16059-64; PMID:8101846
28. Crettol S, Digon P, Golay KP, Brawand M, Eap CB. In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology 2007; 80:304-11; PMID:17690563; http://dx.doi.org/10.1159/000107104
29. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 2000; 40:389-430; PMID:10836142; http://dx.doi.org/10.1146/annurev.pharmtox.40.1.389
30. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124:511-5; PMID:19003982; http://dx.doi.org/10.1002/ijc.24064
31. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108:153-64; PMID:11832206; http://dx.doi.org/10.1016/S0092-8674(02)00625-6
32. Blagosklonny MV. Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget 2012; 3:1711-24; PMID:23565531
33. Golstein P, Ojcius DM, Young JD. Cell death mechanisms and the immune system. Immunol Rev 1991; 121:29-65; PMID:1937533; http://dx.doi.org/10.1111/j. 1600-065X.1991.tb00822.x
34. Bergman PJ, Harris D. Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Vet Clin North Am Small Anim Pract 1997; 27:47-57; PMID:9002166
35. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010; 67:279-83; PMID:20212224; http://dx.doi.org/10. 1001/archneurol.2010.5
36. Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, et al. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and overrides resistance to temozolomide. Oncotarget 2012; 3:1112-23; PMID:23047041
37. Boucher MJ, Duchesne C, Lainé J, Morisset J, Rivard N. cAMP protection of pancreatic cancer cells against apoptosis induced by ERK inhibition. Biochem Biophys Res Commun 2001; 285:207-16; PMID:11444827; http://dx.doi.org/10.1006/bbrc.2001.5147
38. García-Bermejo L, Pérez C, Vilaboa NE, de Blas E, Aller P. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J Cell Sci 1998; 111:637-44; PMID:9454737
39. Sastry KS, Karpova Y, Prokopovich S, Smith AJ, Essau B, Gersappe A, Carson JP, Weber MJ, Register TC, Chen YQ, et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem 2007; 282:14094-100; PMID:17353197; http://dx.doi.org/10.1074/jbc.M611370200
40. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 2008; 9:595-612; PMID:18565004; http://dx.doi.org/10.1111/j.1526-4637.2008.00461.x
41. Mercadante S. Opioid titration in cancer pain: a critical review. Eur J Pain 2007; 11:823-30; PMID:17331764; http://dx.doi.org/10.1016/j.ejpain.2007.01. 003
42. Krantz MJ, Mehler PS. Treating opioid dependence. Growing implications for primary care. Arch Intern Med 2004; 164:277-88; PMID:14769623; http://dx.doi.org/10.1001/archinte.164.3.277
43. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14:8205-12; PMID:19088037; http://dx.doi.org/10.1158/1078-0432.CCR-08-0644
44. Friesen C, Uhl M, Pannicke U, Schwarz K, Miltner E, Debatin K-M. DNA-ligase IV and DNA-protein kinase play a critical role in deficient caspases activation in apoptosis-resistant cancer cells by using doxorubicin. Mol Biol Cell 2008; 19:3283-9; PMID:18508926; http://dx.doi.org/10.1091/mbc.E08-03-0306
45. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256:42-9; PMID:10739650; http://dx.doi.org/10.1006/excr.2000. 4838
46. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin K-M. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997; 90:3118-29; PMID:9376593
47. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8:808-15; PMID:12118245
48. Schimmer AD, Dalili S. Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematology Am Soc Hematol Educ Program 2005:215-9; PMID:16304383; http://dx.doi.org/10.1182/asheducation-2005.1.215
49. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26:1324-37; PMID:17322918; http://dx.doi.org/10.1038/sj. onc.1210220
50. Gabellini C, Castellini L, Trisciuoglio D, Kracht M, Zupi G, Del Bufalo D. Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma. J Neurochem 2008; 107:871-82; PMID:18786178; http://dx.doi.org/10.1111/j.1471-4159.2008.05661.x
51. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 2008; 68:6271-80; PMID:18676851; http://dx.doi.org/10.1158/0008-5472.CAN-07-6769
52. Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 2011; 17:4019-30; PMID:21525171; http://dx.doi.org/10.1158/1078-0432.CCR-11-0075
53. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006; 13:1238-41; PMID:16456578; http://dx.doi.org/10.1038/sj.cdd.4401872
54. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9; PMID:1710634; http://dx.doi.org/10.1016/0022-1759(91)90198-O
55. Friesen C, Kiess Y, Debatin K-M. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ 2004; 11(Suppl 1):S73-85; PMID:15105835; http://dx.doi.org/10.1038/sj. cdd.4401431
56. Roscher M, Hormann I, Leib O, Marx S, Moreno J, Miltner E, Friesen C. Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells. Oncotarget 2013; 4:218-30; PMID:23474846
57. Durand RE. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res 1981; 41:3495-8; PMID:7260912
58. Durand RE, Olive PL. Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res 1981; 41:3489-94; PMID:7020929
59. Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L, Rick FG. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Oncotarget 2013; 4:422-32; PMID:23518876
60. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, et al.; Committee of the National Cancer Research Institute. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102:1555-77; PMID:20502460; http://dx.doi.org/10.1038/sj.bjc.6605642